US-based Illumina, a global leader in DNA sequencing and array-based technologies, and HaploX, a China-based high-tech company specialising in oncology liquid biopsy and genetic big data, have jointly announced the official launch of the first NextSeq 2000Dx-CN-HAP, a domestically-produced genetic sequencing system, in Shenzhen.

This marks a new stage in the strategic partnership between the two companies. In the future, Illumina and HaploX will take the localised manufacturing of high-end life science instruments as a new starting point, focus on scientific research and innovation, and leverage the advantages of the Guangdong-Hong Kong-Macao Greater Bay Area, to jointly support the development of China's life sciences and medical innovation into a new stage.

According to the Outline Development Plan for the Guangdong-Hong Kong-Macao Greater Bay Area, by 2035, the development of the Greater Bay Area will be primarily driven by innovation, and it will take deep participation in international cooperation to build an international science and technology innovation center, enhancing global influence. 

Shenzhen, as a central point in the regional science and technology innovation landscape, gathers international innovation resources and focuses on emerging industries such as high-performance medical devices, genetic sequencing, bioinformatics analysis, etc., aiming to create a new highland for biomedical innovation in China.

NextSeq 2000 sequencing system incorporates over 75 technological innovations and integrates bioinformatics analysis capabilities with the onboard DRAGEN server, enabling complete library amplification, sequencing, and rapid genomic analysis in a one-stop manner.